Treatment Outcomes of Tocilizumab in Critically-Ill COVID-19 Patients, Single-Centre Retrospective Study

• Main Authors: Wael Hafez (Author), Mohamad Azzam Ziade (Author), Arun Arya (Author), Husam Saleh (Author), Mahmoud Abdelshakor (Author), Osman Fadl Alla (Author), Pragati Agrawal (Author), Sara Ali (Author), Srinivasa Raghu Rao (Author), Subrata Gupta (Author), Ikram Abdelli (Author), Honeymol Sebastian (Author), Mohamed Ali (Author), Muneir Gador (Author), Ziad Al Baha (Author), Ahmed Abdelrahman (Author)
• Format: Book
• Published: MDPI AG, 2022-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

(1) Background: Severe COVID-19 outcomes are associated with cytokine release syndrome, characterized by the release of several immune modulators, including Interleukin-6 (IL-6). Tocilizumab (TCZ) is an IL-6 receptor antagonist used to treat rheumatic arthritis. The study aimed to evaluate the effic...